Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computerized Cognitive Skill Training, CRT and Social Cognition
Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
Conditions
Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions
Pioglitazone, Life style diet group, Placebo
Drug · Behavioral · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenia
Interventions
Visual Training
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Piscataway, New Jersey
Conditions
Schizophrenia
Interventions
MK-0777, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Family CTI on Homeless Children

NCT00055081
Conditions
Mental Health
Interventions
Critical Time Intervention
Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Months to 16 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Psychiatric Consequences of Cannabis Use in Adolescents

NCT06941298
Conditions
Cannabis Use, Depression
Interventions
Neuroimaging Investigation
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
14 Years to 20 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Miami, Florida • Orangeburg, New York
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D-serine, placebo, Sensory Based remediation paradigm
Drug · Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Obsessive Compulsive Disorder
Interventions
glycine, placebo
Drug · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Orangeburg, New York
Terminated Phase 2 Interventional Results available

Ketamine in Borderline Personality Disorder

NCT03395314
Conditions
Borderline Personality Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Opioid Use Disorder
Interventions
PRC supported text + AI driven SDH-enhanced text, AI driven SDH-enhanced text only, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Post-Traumatic Stress Disorder
Interventions
STAIR/NT treatment, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Completed Phase 2 Interventional Results available

Safety Study of Pyridostigmine in Heart Failure

NCT01415921
Conditions
Heart Failure
Interventions
Pyridostigmine Bromide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenia, Cognition, Cigarette Smoking
Interventions
tDCS
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenic Disorders, Cognitive Function
Interventions
Sodium Butyrate, Placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia
Interventions
Org 24448, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Completed Phase 1Phase 2 Interventional Results available

D-serine Augmentation of Neuroplasticity

NCT03711500
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Completed Not applicable Interventional Results available

Remediation of Auditory Recognition in Schizophrenia With tDCS

NCT02869334
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Active Transcranial direct current stimulation (tDCS), Sham Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
Device · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Dan Iosifescu
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Capsule with folate, Vitamin B12 & pyridoxine, placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia
Interventions
Cognitive remediation therapy
Behavioral
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

D-serine and Cognitive Remediation in Schizophrenia

NCT02156908
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orangeburg, New York